Molecular NeuroImaging provides neuroimaging research services to the pharmaceutical and biotech industries. By focusing on developing radioligands as tools for human research, we will improve early diagnosis and rapid drug development for neurodegenerative and neuropsychiatric disorders. MNI key activities: * Radioligand development * Early phase human drug-trials-displacement/occupancy * Large scale Phase II-IV clinical imaging trials. * Multi-center quantitative imaging trials - Clinical imaging site coordination as a technical CRO - Core image processing laboratory * Biomarker development – presymptomatic and disease progression.